Reuters logo
BRIEF-Matinas BioPharma Holdings Q2 loss per share $0.40
2017年8月8日 / 上午10点16分 / 3 个月前

BRIEF-Matinas BioPharma Holdings Q2 loss per share $0.40

Aug 8 (Reuters) - Matinas BioPharma Holdings Inc

* Matinas BioPharma reports 2017 second quarter financial results and reaffirms clinical and regulatory strategy to advance mat2203 and mat2501

* Q2 loss per share $0.40

* Q2 earnings per share view $-0.05 -- Thomson Reuters I/B/E/S

* Matinas BioPharma Holdings Inc - ‍company will advance mat2501 into multiple ascending dose phase 1 study in q4 2017​

* Matinas - ‍plans to engage FDA to review data package generated with mat2203 with goal to enter phase 3 for prevention of invasive fungal infections

* Matinas - expects cash on hand at june 30, other cash available to be sufficient to meet operating obligations for at least a year​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below